These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32150602)

  • 1. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
    Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
    Walensky RP; Sax PE; Nakamura YM; Weinstein MC; Pei PP; Freedberg KA; Paltiel AD; Schackman BR
    Ann Intern Med; 2013 Jan; 158(2):84-92. PubMed ID: 23318310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C
    AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
    Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
    J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.
    Leech AA; Burgess JF; Sullivan M; Kuohung W; Horný M; Drainoni ML; Christiansen CL; Linas BP
    AIDS; 2018 Nov; 32(18):2787-2798. PubMed ID: 30234602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G; Sauermilch D; Gandhi M; Starks TJ
    AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
    Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
    Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E
    Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.
    Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY
    Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
    Arribas JR; Thompson M; Sax PE; Haas B; McDonald C; Wohl DA; DeJesus E; Clarke AE; Guo S; Wang H; Callebaut C; Plummer A; Cheng A; Das M; McCallister S
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):211-218. PubMed ID: 28282300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.
    Wohl DA; Spinner CD; Flamm J; Hare CB; Doblecki-Lewis S; Ruane PJ; Molina JM; Mills A; Brinson C; Ramgopal M; Clarke A; Crofoot G; Martorell C; Carter C; Cox S; Hojilla JC; Shao Y; Das M; Kintu A; Baeten JM; Grant RM; Mounzer K; Mayer K
    Lancet HIV; 2024 Aug; 11(8):e508-e521. PubMed ID: 39008999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and benefits of on-demand HIV preexposure prophylaxis in MSM.
    Durand-Zaleski I; Mutuon P; Charreau I; Tremblay C; Rojas D; Pialoux G; Chidiac C; Capitant C; Spire B; Cotte L; Chas J; Meyer L; Molina JM;
    AIDS; 2018 Jan; 32(1):95-102. PubMed ID: 29210777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults.
    Mesplède T
    Expert Opin Pharmacother; 2021 Jul; 22(10):1245-1251. PubMed ID: 33691554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Cambiano V; Miners A; Dunn D; McCormack S; Ong KJ; Gill ON; Nardone A; Desai M; Field N; Hart G; Delpech V; Cairns G; Rodger A; Phillips AN
    Lancet Infect Dis; 2018 Jan; 18(1):85-94. PubMed ID: 29054789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
    Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M
    Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
    Marrazzo J; Tao L; Becker M; Leech AA; Taylor AW; Ussery F; Kiragu M; Reza-Paul S; Myers J; Bekker LG; Yang J; Carter C; de Boer M; Das M; Baeten JM; Celum C
    JAMA; 2024 Mar; 331(11):930-937. PubMed ID: 38427359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
    Nichols BE; Boucher CAB; van der Valk M; Rijnders BJA; van de Vijver DAMC
    Lancet Infect Dis; 2016 Dec; 16(12):1423-1429. PubMed ID: 27665989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.